Patents by Inventor Christopher M. Mapes

Christopher M. Mapes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
    Publication number: 20090137608
    Abstract: Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for H4 receptor activity modulation and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 28, 2009
    Inventors: James P. EDWARDS, David E. KINDRACHUK, Christopher M. MAPES, Daniel J. PIPPEL, Jennifer D. VENABLE
  • Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine Hreceptor
    Patent number: 7507737
    Abstract: Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: March 24, 2009
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: James P. Edwards, David E. Kindrachuk, Christopher M. Mapes, Daniel J. Pippel, Jennifer D. Venable
  • Retinoid X receptor modulators
    Patent number: 7348359
    Abstract: The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: March 25, 2008
    Assignees: Eli Lilly and Company, Ligand Pharmaceuticals
    Inventors: Kevin M. Gardinier, Douglas L. Gernert, Timothy A. Grese, David A. Neel, Christopher M. Mapes, Pierre-Yves Michellys, Marcus F. Boehm
  • Fluorinated trienes and their use as rxr modulators
    Publication number: 20040248919
    Abstract: The present invention relates to a method of modulating retinoid X receptor activity in a mammal, novel compounds and pharmaceutical compositions for modulating retinoid X receptor activity in a mammal, and methods of making compounds that modulate retinoid X receptor activity in a mammal. The compounds are represented by Structural Formula 1: The compounds of Structural Formual 1 are efficacious insulin sensitizers and do not have the undesirable side effects of increasing triglycerides or suppressing the thyroid hormone axis.
    Type: Application
    Filed: April 15, 2004
    Publication date: December 9, 2004
    Inventors: Michael Gregory Bell, Timothy Alan Grese, Douglas Linn Gernett, Nathan P. Yumibe, Marcus F. Boehm, Pierre-Yves Michellys, Robert J. Ardecky, Christopher M Mapes, Jyun-Hung Chen, John S. Tyhonas, Lawrence G. Hamann
  • Retinoid x receptor modulators
    Publication number: 20040167160
    Abstract: The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.
    Type: Application
    Filed: January 16, 2004
    Publication date: August 26, 2004
    Inventors: Kevin M. Gardinier, Douglas J. Gernert, Timothy A. Grese, David A. Neel, Christopher M. Mapes, Pierre-Yves Michellys, Marcus F. Boehm
  • RXR modulators with improved pharmacologic profile
    Publication number: 20040049072
    Abstract: The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.
    Type: Application
    Filed: May 9, 2003
    Publication date: March 11, 2004
    Inventors: Robert J. Ardecky, Marcus F. Boehm, Amy L. Faulkner, Lawrence G. Hamann, Todd K. Jones, Christopher M. Mapes, Pierre-Yves Michellys, John S. Tyhonas
  • RXR modulators with improved pharmacologic profile
    Patent number: 6593493
    Abstract: The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: July 15, 2003
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Robert J. Ardecky, Marcus F. Boehm, Amy L. Faulkner, Lawrence G. Hamann, Todd K. Jones, Christopher M. Mapes, Pierre-Yves Michellys, John S. Tyhonas, Anthony W. Thompson, Jyun-Hung Chen